GlaxoSmithKline reported Q1 2018 results that were in-line with consensus. The market has been disappointed by the performance of Respiratory and HIV divisions. Even if the stock has de-rated from 10.9x to 8.8x NTM EV/EBITDA, I still …
Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views. (WebFG News) - GlaxoSmithKline reported underlying sales growth across all three businesses in the first quarter but earnings down almost half as it …
GlaxoSmithKline PLC (GSK.LN) said Wednesday that net profit fell 48% as revenue declined on currency headwinds in the first quarter, and said that it backed its full-year guidance. The pharmaceutical company said that net profit for the …
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing …
Weighing up these factors and with the Pfizer uncertainty removed, I believe that now could be a good time to take a closer look at the stock. More reading Edward …